Users Online: 126
Home Print this page Email this page
Home About us Editorial board Search Browse articles Submit article Ahead of Print Instructions Subscribe Contacts Special issues Login 


 
Previous article Browse articles Next article 
CASE REPORT
Adv Biomed Res 2018,  7:83

Subcorneal Pustular Dermatosis: A Case Report of a Patient with Diffuse Scleroderma


Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Date of Web Publication23-May-2018

Correspondence Address:
Dr. Nazila Poostiyan
Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/abr.abr_21_17

Rights and Permissions
  Abstract 


Subcorneal pustular dermatosis (SPD) or Sneddon-Wilkinson disease is a rare, benign, chronic, sterile pustular eruption which is associated with various systemic diseases including immunoglobinopathies, neoplasms, and autoimmune disorders. This paper reports a case of SPD in a patient with diffuse scleroderma in a 37-year-old woman. The hypothesis that immune dysregulation may play a role in the pathogenesis of SPD was supposed by the coexistence of diffuse scleroderma and SPD in our patient.

Keywords: Diffuse scleroderma, immune dysregulation, subcorneal pustular dermatosis


How to cite this article:
Mokhtari F, Poostiyan N. Subcorneal Pustular Dermatosis: A Case Report of a Patient with Diffuse Scleroderma. Adv Biomed Res 2018;7:83

How to cite this URL:
Mokhtari F, Poostiyan N. Subcorneal Pustular Dermatosis: A Case Report of a Patient with Diffuse Scleroderma. Adv Biomed Res [serial online] 2018 [cited 2023 Mar 23];7:83. Available from: https://www.advbiores.net/text.asp?2018/7/1/83/233026




  Introduction Top


Subcorneal pustular dermatosis (SPD) or Sneddon-Wilkinson is a rare, benign, chronic, sterile pustular eruption which is common in middle-aged or elderly women. It was originally described in 1956.[1] SPD is associated with various systemic diseases including immunoglobinopathies, neoplasms, and autoimmune disorders.[2],[3],[4],[5] This paper reports a case of SPD in a patient with diffuse scleroderma in a 37-year-old woman.


  Case Report Top


A 37-year-old female patient was admitted to our hospital with a 2-week history of recurrent generalized pruritic pustular eruption located mainly on the trunk and the extremities. No diagnosis and treatment procedures were made for the patient before her first visit in our unit. Her past medical history was notable for the presence of diffuse scleroderma for the past 7 years. Her medications included atenolol, valsartan, hydroxychloroquine, furosemide, and nifedipine. The dermatologic examination showed superficial vesicles and pustules located on normal skin or erythematous base of the trunk and the extremities. Gravity-induced demarcation could hardly be seen. The face, palms, soles, and mucous membranes were spared [Figure 1], [Figure 2], [Figure 3]. No lymphadenopathy or hepatosplenomegaly was presented. Physical examination showed a “bird-like” face with a beaked nose, telangiectasia, and radial furrowing around the lips. The fingers had a smooth, shiny, tapered appearance with the nails curving over the atrophic phalanges.
Figure 1: Patient's lesions 1

Click here to view
Figure 2: Patient's lesions 2

Click here to view
Figure 3: Patient's lesions 3

Click here to view


The differential diagnosis included SPD, IgA-pemphigus, pustular psoriasis, and tinea. Because there was no history of exposure to a new drug, acute generalized exanthematous pustulosis (AGEP) was not considered in differential diagnosis. Cultures of the pustules were sterile. Biopsies were taken for light microscopy and direct immunofluorescence examinations. Microscopic examinations demonstrated acanthosis, focal parakeratosis, subcorneal pustules, and crust in the epidermis. A few acantholytic cells were identified. Focal vacuolar degeneration of the basal layer, infiltration of lymphocytes, and a few eosinophils accompanied by focal edema of papillary dermis were observed [Figure 4]. Direct immunofluorescence examination was negative. The diagnosis of SPD of Sneddon and Wilkinson was made based on the clinical and histopathological findings.
Figure 4: Histopathology

Click here to view


Results of laboratory examinations including complete blood count, serum chemistries, serum protein electrophoresis, urine protein electrophoresis, and glucose-6-phosphate dehydrogenase (G6PD) were normal.

When the normal level of G6PD was confirmed, our patient was started on dapsone at a dosage of 50 mg daily, topical steroid twice daily, Burow's solution every 8 h, and oral hydroxyzine 25 mg daily. She refused to take dapsone and continued on topical medications for 2 weeks. Although the patient initially responded to topical therapy, the disease recurred two times during a 3-month follow-up. Dapsone was prescribed for the patient again, but she refused to take the drug and did not refer to our hospital.


  Discussion Top


SPD or  Sneddon-Wilkinson disease More Details was originally described in 1956.[1] This rare, benign, chronic, sterile pustular eruption usually develops in middle-aged or elderly women.[2],[3],[4],[5] The lesions coalesce into annular, circinate, or serpiginous patterns and involving more frequently the trunk, intertriginous areas, and flexor aspects of the limbs. The face, palms, soles and mucous membranes are usually unaffected in this disorder.[4],[5]

The differential diagnosis includes pustular psoriasis, subcorneal-type IgA pemphigus, pemphigus foliaceus, dermatitis herpetiformis, dermatophyte infection, and acute AGEP. Moreover, some laboratory tests such as histopathological and immunofluorescence assays, culture of the pustules, and recent drug history are needed to rule out other diagnosis.[2],[4],[5]

SPD presents alone or with various systemic diseases including immunoglobinopathies, neoplasms, and autoimmune disorders such as benign monoclonal IgA, IgG, and IgM gammopathy, multiple myeloma, marginal zone lymphoma, rheumatoid arthritis, seronegative polyarthritis, Sjögren disease, and systemic lupus erythematosus.[2],[3],[4],[5],[6],[7],[8],[9]

Diffuse scleroderma is a multisystem disease manifested by fibrosis, vasculopathy, and disordered immune system.[2],[10],[11],[12] The hypothesis that immune dysregulation may play a role in the pathogenesis of SPD is supported by the coexistence of diffuse scleroderma and SPD in our patient. SPD is more frequent among women aged 40 years or older;[3],[5] however, in our patient, it developed under the age of 40. The appearance of the disorder in our patient before her forties may be associated with the coexistence of SPD with diffuse scleroderma. A case report by Brantley and Shethdescribed a 37-year-old female patient with SPD who had past medical history of rheumatoid arthritis and diffuse scleroderma.[2] In the study, underlying systemic immunologic defect was also noted as an important factor in the coexistence of SPD with rheumatoid arthritis and diffuse scleroderma. The patient was treated with dapsone and was stable after 9-month follow-up. The recurrence of disease in our patient with topical therapy suggesting the importance of dapsone in the treatment of SPD.


  Conclusion Top


SPD may associate with underlying diffuse scleroderma and occur in the lower age in association with connective tissue diseases.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no confl icts of interest.



 
  References Top

1.
Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol 1956;68:385-94.  Back to cited text no. 1
[PUBMED]    
2.
Brantley EI, Sheth P. Subcorneal pustular dermatosis in a patient with rheumatoid arthritis and diffuse scleroderma. Dermatol Online J 2009;15:5.  Back to cited text no. 2
    
3.
Abreu Velez AM, Smith JG Jr., Howard MS. Subcorneal pustular dermatosis an immnohisto-pathological perspective. Int J Clin Exp Pathol 2011;4:526-9.  Back to cited text no. 3
    
4.
Ratnarathorn M, Newman J. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: A case report. Dermatol Online J 2008;14:6.  Back to cited text no. 4
    
5.
Scalvenzi M, Palmisano F, Annunziata MC, Mezza E, Cozzolino I, Costa C. Subcorneal pustular dermatosis in childhood: A case report and review of the literature. Case Rep Dermatol Med 2013;2013:424797.  Back to cited text no. 5
[PUBMED]    
6.
Cartier H, Plantin P, Leroy JP, Larzul JJ. Pyoderma gangrenosum, subcorneal IgA pustulosis and recurrent neutrophilic pleural and pulmonary diseases in a patient with IgA gammopathy. Ann Dermatol Venereol 1995;122:97-101.  Back to cited text no. 6
[PUBMED]    
7.
Villasante De La Puente A, Hormaechea Beldarrain JA, García Aguinaga ML, Vera López E, Gilsanz Fernández C. Pustulosis of Sneddon Wilkinson disease and multiple myeloma. An Med Interna 2001;18:373-5.  Back to cited text no. 7
    
8.
Tsuruta D, Matsumura-Oura A, Ishii M. Subcorneal pustular dermatosis and Sjögren's syndrome. Int J Dermatol 2005;44:955-7.  Back to cited text no. 8
[PUBMED]    
9.
Saulsbury FT, Kesler RW. Subcorneal pustular dermatosis and systemic lupus erythematosus. Int J Dermatol 1984;23:63-4.  Back to cited text no. 9
[PUBMED]    
10.
Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of Disease: The role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:679-85.  Back to cited text no. 10
[PUBMED]    
11.
Medsger TA Jr., Ivanco DE, Kardava L, Morel PA, Lucas MR, Fuschiotti P. GATA-3 up-regulation in CD8+T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 2011;63:1738-47.  Back to cited text no. 11
    
12.
Hudson M, Fritzler MJ. Diagnostic criteria of systemic sclerosis. J Autoimmun 2014;48-49:38-41.  Back to cited text no. 12
[PUBMED]    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]



 

Top
Previous article  Next article
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Case Report
Discussion
Conclusion
References
Article Figures

 Article Access Statistics
    Viewed2916    
    Printed90    
    Emailed0    
    PDF Downloaded234    
    Comments [Add]    

Recommend this journal